Sugemalimab: First Approval

Article Oncology

Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial

Jifang Gong et al.

Summary: This first-in-human phase 1 trial evaluated the safety, pharmacokinetics, preliminary efficacy, and biomarkers of sugemalimab in Chinese patients with advanced malignancies. The results showed that sugemalimab was well-tolerated and demonstrated promising antitumor activity as monotherapy or in combination with chemotherapy.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

添加到收藏夹

Article Oncology

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial

Caicun Zhou et al.

Summary: The GEMSTONE-302 trial showed that sugemalimab plus chemotherapy significantly improved progression-free survival in previously untreated squamous and non-squamous metastatic NSCLC patients compared to placebo plus chemotherapy, regardless of PD-L1 expression. These findings have important implications for the first-line treatment of squamous and non-squamous metastatic NSCLC.

LANCET ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

Li Jin et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Next generation of immune checkpoint inhibitors and beyond

Julian A. Marin-Acevedo et al.

Summary: The immune system plays a crucial role in defending against cancer, but tumor cells can evade immune recognition. Immunotherapy enhances host immune response to combat tumors.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

The preclinical characterization of CS1001, an anti-PD-L1 IgG4 monoclonal antibody and its activity beyond T cell regulation

Juan Zhang et al.

CANCER RESEARCH (2020)

添加到收藏夹

Meeting Abstract Hematology

Preliminary Results from a Multicenter, Single-Arm, Phase 2 Study of CS1001, an Anti-Programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mAb), in Patients (pts) with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (rr-ENKTL)

Hui-qiang Huang et al.

BLOOD (2019)

添加到收藏夹

Sugemalimab: First Approval

相关参考文献

Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial

CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

Next generation of immune checkpoint inhibitors and beyond

The preclinical characterization of CS1001, an anti-PD-L1 IgG4 monoclonal antibody and its activity beyond T cell regulation

Preliminary Results from a Multicenter, Single-Arm, Phase 2 Study of CS1001, an Anti-Programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mAb), in Patients (pts) with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (rr-ENKTL)

导出引文

分享论文